Literature DB >> 8559171

Isaacs' syndrome associated with chronic inflammatory demyelinating polyneuropathy.

Z Odabasi1, J L Joy, G C Claussen, G A Herrera, S J Oh.   

Abstract

We report the first case of Isaacs' syndrome in which an inflammatory demyelinating neuropathy was documented histologically. For 9 months, the patient developed slowly progressive weakness, muscle spasms and stiffness, fasciculations, and myokymia in the arms, which were unmodified by sleep. Nerve conduction studies showed multifocal motor conduction block, abnormal dispersion phenomenon, and abnormal sensory and mixed nerve conduction. Needle electromyogram showed continuous motor unit potentials at rest with bursts of rapid-firing discharges which were unaffected by spinal anesthesia but diminished by peripheral nerve block and completely abolished by local curarization. Sural nerve biopsy demonstrated an inflammatory demyelinating neuropathy. Muscle cramping, twitching, and stiffness responded to phenytoin. The patient's weakness gradually responded to prednisone and azathioprine. Over a 17-year period, the patient had three relapses which were well controlled with prednisone and azathioprine. At this time, the patient is symptom-free without any medication.

Entities:  

Mesh:

Year:  1996        PMID: 8559171     DOI: 10.1002/(SICI)1097-4598(199602)19:2<210::AID-MUS13>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  The novel homozygous KCNJ10 c.986T>C (p.(Leu329Pro)) variant is pathogenic for the SeSAME/EAST homologue in Malinois dogs.

Authors:  Mario Van Poucke; Kimberley Stee; Sofie F M Bhatti; An Vanhaesebrouck; Leslie Bosseler; Luc J Peelman; Luc Van Ham
Journal:  Eur J Hum Genet       Date:  2016-12-14       Impact factor: 4.246

2.  A case of Isaacs' syndrome associated with spinal muscular atrophy.

Authors:  İsmail Koç; Serkan Çelik; Mehmet Emin Dağ; Ömer Karadaş; Zeki Odabaşı
Journal:  Acta Neurol Belg       Date:  2020-11-04       Impact factor: 2.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.